Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381719 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT00381719 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 330 participants.
The verdict
NCT00381719, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
Interventions
- DRUG placebo capsule
- DRUG AGN 203818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381719
The ClinicalTrials.gov registry entry for NCT00381719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo capsule is the first listed.
NCT00381719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381719 about?
NCT00381719 is a clinical study titled "Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy". This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
What is the current status of trial NCT00381719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00381719?
The interventions under investigation include: placebo capsule (DRUG), AGN 203818 (DRUG).
Who is sponsoring clinical trial NCT00381719?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.